Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Renal involvement in primary Sjögren's syndrome: a clinicopathologic study.

Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, Hogan MC.

Clin J Am Soc Nephrol. 2009 Sep;4(9):1423-31. doi: 10.2215/CJN.00980209. Epub 2009 Aug 13.

2.

Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil.

Raatz SK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM.

J Am Diet Assoc. 2009 Jun;109(6):1076-81. doi: 10.1016/j.jada.2009.03.006.

3.

Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.

Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio JV Jr, Holub BJ; Southwest Pediatric Nephrology Study Group.

Clin J Am Soc Nephrol. 2006 May;1(3):467-74. Epub 2006 Apr 12.

4.

Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?

Donadio JV, Bergstralh EJ, Bibus DM, Grande JP.

Clin J Am Soc Nephrol. 2006 Sep;1(5):933-9. Epub 2006 Aug 2.

5.

The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy.

Donadio JV, Grande JP.

Semin Nephrol. 2004 May;24(3):225-43. Review.

PMID:
15156528
6.

IgA nephropathy.

Donadio JV, Grande JP.

N Engl J Med. 2002 Sep 5;347(10):738-48. Review. No abstract available.

PMID:
12213946
7.

Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.

Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM.

Nephrol Dial Transplant. 2002 Jul;17(7):1197-203.

PMID:
12105241
8.

Role of dietary fish oil supplementation in IgA nephropathy. Mechanistic implications.

Grande JP, Donadio JV.

Minerva Urol Nefrol. 2001 Dec;53(4):201-9. Review.

PMID:
11753248
9.

n-3 Fatty acids and their role in nephrologic practice.

Donadio JV.

Curr Opin Nephrol Hypertens. 2001 Sep;10(5):639-42. Review.

PMID:
11496058
10.
11.

A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy.

Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP.

J Am Soc Nephrol. 2001 Apr;12(4):791-9.

12.

Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo.

Grande JP, Walker HJ, Holub BJ, Warner GM, Keller DM, Haugen JD, Donadio JV Jr, Dousa TP.

Kidney Int. 2000 Mar;57(3):1027-40.

13.

Use of fish oil to treat patients with immunoglobulin a nephropathy.

Donadio JV Jr.

Am J Clin Nutr. 2000 Jan;71(1 Suppl):373S-5S. doi: 10.1093/ajcn/71.1.373s. Review.

PMID:
10618000
14.

Recurrent Goodpasture's disease due to a monoclonal IgA-kappa circulating antibody.

Fervenza FC, Terreros D, Boutaud A, Hudson BG, Williams RA Jr, Donadio JV Jr, Schwab TR.

Am J Kidney Dis. 1999 Sep;34(3):549-55.

PMID:
10469867
15.

The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.

Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC.

J Am Soc Nephrol. 1999 Aug;10(8):1772-7.

16.

Dietary fish oil supplementation in IgA nephropathy: a therapy in search of a mechanism?

Grande JP, Donadio JV Jr.

Nutrition. 1998 Feb;14(2):240-2. No abstract available.

PMID:
9530656
17.

Immunoglobulin A nephropathy: a clinical perspective.

Donadio JV Jr, Grande JP.

J Am Soc Nephrol. 1997 Aug;8(8):1324-32. Review. No abstract available.

18.

The fate of renal transplants in patients with IgA nephropathy.

Frohnert PP, Donadio JV Jr, Velosa JA, Holley KE, Sterioff S.

Clin Transplant. 1997 Apr;11(2):127-33.

PMID:
9113449
19.

Predicting renal outcome in IgA nephropathy.

Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP.

J Am Soc Nephrol. 1997 Feb;8(2):199-207.

20.

Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs.

Radford MG Jr, Holley KE, Grande JP, Larson TS, Wagoner RD, Donadio JV, McCarthy JT.

JAMA. 1996 Aug 14;276(6):466-9.

PMID:
8691554
21.

Prognostic determinants in lupus nephritis: a long-term clinicopathologic study.

Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE.

Lupus. 1995 Apr;4(2):109-15.

PMID:
7795613
22.

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group.

Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE.

N Engl J Med. 1994 Nov 3;331(18):1194-9.

23.

Renal biopsy in clinical practice.

Radford MG Jr, Donadio JV Jr, Holley KE, Björnsson J, Grande JP.

Mayo Clin Proc. 1994 Oct;69(10):983-4. Review. No abstract available.

PMID:
7934195
24.

Renal transplantation in IgA nephropathy: the effect of HLA matching on recurrence of primary disease.

Frohnert PP, Velosa JA, Donadio JV, Sterioff S.

Transplant Proc. 1994 Aug;26(4):1892. No abstract available.

PMID:
8066615
25.

Essential fatty acid deficiency profiles in idiopathic immunoglobulin A nephropathy.

Holman RT, Johnson SB, Bibus D, Spencer DC, Donadio JV Jr.

Am J Kidney Dis. 1994 May;23(5):648-54.

PMID:
8172206
26.

Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group.

Donadio JV, Bergstralh EJ, Offord KP, Holley KE, Spencer DC.

Clin Nephrol. 1994 Feb;41(2):65-71.

PMID:
8004831
27.

Immunosuppressive drug therapy in lupus nephritis.

Donadio JV Jr, Glassock RJ.

Am J Kidney Dis. 1993 Mar;21(3):239-50. Review.

PMID:
8447299
28.

Treatment and clinical outcome of glomerulonephritis in the elderly.

Donadio JV Jr.

Contrib Nephrol. 1993;105:49-57. Review. No abstract available.

PMID:
8252871
29.

Treatment of membranous nephropathy in systemic lupus erythematosus.

Donadio JV Jr.

Nephrol Dial Transplant. 1992;7 Suppl 1:97-104. Review. No abstract available.

PMID:
1337190
30.

Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease.

Donadio JV Jr.

Mayo Clin Proc. 1991 Oct;66(10):1018-28. Review.

PMID:
1921484
31.

Elevated urinary excretion of the C5b-9 complex in membranous nephropathy.

Schulze M, Donadio JV Jr, Pruchno CJ, Baker PJ, Johnson RJ, Stahl RA, Watkins S, Martin DC, Wurzner R, Gotze O, et al.

Kidney Int. 1991 Sep;40(3):533-8.

32.

De novo systemic vasculitis in a renal transplant recipient.

Schriner RW, Nada AK, Lie JT, Wilhelm MP, Sterioff S, Donadio JV Jr.

Mayo Clin Proc. 1991 Feb;66(2):183-6.

PMID:
1671607
33.

Failure to detect cytomegalovirus DNA in IgA nephropathy by polymerase chain reaction.

Telenti A, Donadio JV Jr, Smith TF.

J Am Soc Nephrol. 1990 Nov;1(5):841. No abstract available.

34.

Treatment of glomerulonephritis in the elderly.

Donadio JV Jr.

Am J Kidney Dis. 1990 Oct;16(4):307-11. Review.

PMID:
2220775
35.

Risk factors in idiopathic renal vasculitis and glomerulonephritis.

Wilkowski MJ, Velosa JA, Holley KE, Offord KP, Chu CP, Torres VE, McCarthy JT, Donadio JV Jr, Wagoner RD.

Kidney Int. 1989 Dec;36(6):1133-41.

36.
37.

Idiopathic membranous nephropathy: the natural history of untreated patients.

Donadio JV Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP.

Kidney Int. 1988 Mar;33(3):708-15.

38.

Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study.

Donadio JV Jr, Ilstrup DM, Holley KE, Romero JC.

Mayo Clin Proc. 1988 Jan;63(1):3-15.

PMID:
3336239
39.

Blood pressure determinants in living-related renal allograft donors and their recipients.

Torres VE, Offord KP, Anderson CF, Velosa JA, Frohnert PP, Donadio JV Jr, Wilson DM.

Kidney Int. 1987 Jun;31(6):1383-90.

40.

Renal involvement in relapsing polychondritis.

Chang-Miller A, Okamura M, Torres VE, Michet CJ, Wagoner RD, Donadio JV Jr, Offord KP, Holley KE.

Medicine (Baltimore). 1987 May;66(3):202-17.

PMID:
3574118
41.

Renal biopsy in the adult nephrotic syndrome.

Holley KE, Donadio JV Jr, Wagoner RD, Torres VE, Velosa JA.

Semin Nephrol. 1985 Dec;5(4):274-93. No abstract available.

PMID:
3843804
42.

Use of captopril as early therapy for renal scleroderma: a prospective study.

Beckett VL, Donadio JV Jr, Brennan LA Jr, Conn DL, Osmundson PJ, Chao EY, Holley KE.

Mayo Clin Proc. 1985 Nov;60(11):763-71.

PMID:
3903366
43.

Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study.

Velosa JA, Torres VE, Donadio JV Jr, Wagoner RD, Holley KE, Offord KP.

Mayo Clin Proc. 1985 Sep;60(9):586-92.

PMID:
4021548
44.

Serology in renal disease: a review.

Schwab TR, Donadio JV Jr.

Semin Nephrol. 1985 Sep;5(3):179-87. No abstract available.

PMID:
3843795
45.

The risks of unilateral nephrectomy: status of kidney donors 10 to 20 years postoperatively.

Anderson CF, Velosa JA, Frohnert PP, Torres VE, Offord KP, Vogel JP, Donadio JV Jr, Wilson DM.

Mayo Clin Proc. 1985 Jun;60(6):367-74.

PMID:
3999807
46.

Chemotherapy of lupus nephropathy.

Donadio JV.

Contrib Nephrol. 1985;45:200-2. No abstract available.

PMID:
3884260
47.

Cytotoxic-drug treatment of lupus nephritis.

Donadio JV Jr.

N Engl J Med. 1984 Aug 23;311(8):528-9. No abstract available.

PMID:
6749210
48.

Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy.

Donadio JV Jr, Anderson CF, Mitchell JC 3rd, Holley KE, Ilstrup DM, Fuster V, Chesebro JH.

N Engl J Med. 1984 May 31;310(22):1421-6.

PMID:
6371535
49.

Cytotoxic drug treatment of lupus nephritis.

Donadio JV Jr, Holley KE, Ilstrup DM.

Am J Kidney Dis. 1982 Jul;2(1 Suppl 1):178-81.

PMID:
7102666
50.

The limitations of renal biopsy.

Donadio JV Jr.

Am J Kidney Dis. 1982 Jan;1(4):249-50. No abstract available.

PMID:
7158634

Supplemental Content

Loading ...
Support Center